Serum Metabolic Profile Alteration Reveals Response to Platinum-Based Combination Chemotherapy for Lung Cancer: Sensitive Patients Distinguished from Insensitive ones

doi:10.1038/s41598-017-16085-y

	Serum Metabolic Profile Alteration Reveals Response to Platinum-Based Combination Chemotherapy for Lung Cancer: Sensitive Patients Distinguished from Insensitive ones
	Xu, Shan 3,5,6; Zhou, Yanping 3; Geng, Hui 1; Song, Dandan 3; Tang, Jing 2; Zhu, Xianmin 2; Yu, Di 4; Hu, Sheng 2; Cui, Yanfang 3,4
刊名	SCIENTIFIC REPORTS
	2017-12-13
卷号	7
ISSN号	2045-2322
DOI	10.1038/s41598-017-16085-y
文献子类	Article
英文摘要	Most lung cancers are diagnosed at fairly advanced stages due to limited clinical symptoms. Platinum-based chemotherapy, either as single regimen or in combination with radiation, is one of the major recommendations for the patients. Earlier evaluation of the effectiveness of the chemotherapies is critical for developing better treatment plan given the toxicity of the chemotherapeutic reagents. Drug efficacy could be reflected in the systemic metabolism characteristics though knowledge about which remains scarce. In this study, serum metabolism influence of three types of commonly used platinum-based combination chemotherapy regimens, namely cisplatin with gemcitabine, vinorelbine or docetaxel, were studied using pattern recognition coupled with nuclear magnetic resonance techniques. The treated patients were divided into sensitive or insensitive subgroups according to their response to the treatments. We found that insensitive subjects can be identified from the sensitive ones with up-regulation of glucose and taurine but reduced alanine and lactate concentrations in serum. The combination chemotherapy of lung cancer is accompanied by disturbances of multiple metabolic pathways such as energy metabolism, phosphatidylcholine biosynthesis, so that the treated patients were marginally discriminated from the untreated. Serum metabolic profile of patients shows potential as an indicator of their response to platinum-based combination chemotherapy.
WOS关键词	BREAST-CANCER ; TUMOR-GROWTH ; DNA-REPAIR ; STATISTICS ; RESISTANCE ; CHOLINE ; ERCC1 ; METABONOMICS ; CRIZOTINIB ; INHIBITION
WOS研究方向	Science & Technology - Other Topics
语种	英语
出版者	NATURE PUBLISHING GROUP
WOS记录号	WOS:000417796000044
资助机构	Natural Science Foundation of China(21473065 ; Natural Science Foundation of China(21473065 ; Wuhan Science and Technology RD Program(201060623259 ; Wuhan Science and Technology RD Program(201060623259 ; Natural Science Key Foundation of Hubei(2014CFA079) ; Natural Science Key Foundation of Hubei(2014CFA079) ; 21675059) ; 21675059) ; 200860423220) ; 200860423220) ; Natural Science Foundation of China(21473065 ; Natural Science Foundation of China(21473065 ; Wuhan Science and Technology RD Program(201060623259 ; Wuhan Science and Technology RD Program(201060623259 ; Natural Science Key Foundation of Hubei(2014CFA079) ; Natural Science Key Foundation of Hubei(2014CFA079) ; 21675059) ; 21675059) ; 200860423220) ; 200860423220) ; Natural Science Foundation of China(21473065 ; Natural Science Foundation of China(21473065 ; Wuhan Science and Technology RD Program(201060623259 ; Wuhan Science and Technology RD Program(201060623259 ; Natural Science Key Foundation of Hubei(2014CFA079) ; Natural Science Key Foundation of Hubei(2014CFA079) ; 21675059) ; 21675059) ; 200860423220) ; 200860423220) ; Natural Science Foundation of China(21473065 ; Natural Science Foundation of China(21473065 ; Wuhan Science and Technology RD Program(201060623259 ; Wuhan Science and Technology RD Program(201060623259 ; Natural Science Key Foundation of Hubei(2014CFA079) ; Natural Science Key Foundation of Hubei(2014CFA079) ; 21675059) ; 21675059) ; 200860423220) ; 200860423220)
内容类型	期刊论文
源URL	[http://ir.wipm.ac.cn/handle/112942/12744]
专题	中国科学院武汉物理与数学研究所
通讯作者	Hu, Sheng; Cui, Yanfang
作者单位	1.Cent China Normal Univ, Dept Life Sci, Wuhan 430079, Hubei, Peoples R China 2.Hubei Prov Tumor Hosp, Dept Med Oncol, Wuhan 430079, Hubei, Peoples R China 3.Cent China Normal Univ, Minist Educ, Key Lab Pesticide & Chem Biol, Wuhan 430079, Hubei, Peoples R China 4.Monash Univ, Biomed Discovery Inst, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia 5.Univ Chinese Acad Sci, Wuhan Inst Phys & Math, Natl Ctr Magnet Resonance Wuhan,CAS Key Lab Magne, State Key Lab Magnet Resonance & Atom & Mol Phys, Wuhan 430071, Hubei, Peoples R China 6.Huazhong Univ Sci & Technol, Tongji Med Coll, Wuhan 430030, Hubei, Peoples R China
推荐引用方式 GB/T 7714	Xu, Shan,Zhou, Yanping,Geng, Hui,et al. Serum Metabolic Profile Alteration Reveals Response to Platinum-Based Combination Chemotherapy for Lung Cancer: Sensitive Patients Distinguished from Insensitive ones[J]. SCIENTIFIC REPORTS,2017,7.
APA	Xu, Shan.,Zhou, Yanping.,Geng, Hui.,Song, Dandan.,Tang, Jing.,...&Cui, Yanfang.(2017).Serum Metabolic Profile Alteration Reveals Response to Platinum-Based Combination Chemotherapy for Lung Cancer: Sensitive Patients Distinguished from Insensitive ones.SCIENTIFIC REPORTS,7.
MLA	Xu, Shan,et al."Serum Metabolic Profile Alteration Reveals Response to Platinum-Based Combination Chemotherapy for Lung Cancer: Sensitive Patients Distinguished from Insensitive ones".SCIENTIFIC REPORTS 7(2017).